Biocytogen Announces the Launch of RenSuper Workstation to Accelerate the Antibody Discovery
Published: 03 Jul 2026
Author: Rohan Patil
In May 2026, Biocytogen announced the launch of the RenSuper Workstation, a next-generation AI-powered antibody discovery platform that offers immediate access to a comprehensive, experimentally validated library of fully human therapeutic antibody sequences. This platform is complemented by the RenSuper High-Throughput Antibody Manufacturing Automation Center, an entirely automated infrastructure designed to expedite antibody validation and production.
AI-Powered Target-to-Lead Therapeutic Antibody Discovery
Built on Biocytogen’s proprietary RenMice® platforms, the RenSuper Workstation establishes a closed-loop antibody discovery engine that integrates in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing capabilities. The platform introduces a transformative paradigm for therapeutic antibody discovery, evolving the process from a project-based workflow into a searchable and programmable system, which allows for the rapid identification of high-quality therapeutic candidates with significant developability, functional relevance, and translational potential.
The platform facilitates one-click filtering and comparison of antibody candidates based on target, epitope, and physicochemical properties. An integrated antibody design platform further enhances rapid sequence assembly and flexible format design across multiple therapeutic modalities.
Dr. Yuelei Shen, Founder and CEO of Biocytogen, stated, “We believe the future of antibody discovery will be driven by speed, scale, and data-driven intelligence. With RenSuper, we are establishing an intelligence-native system that renders antibody discovery more intelligent, scalable, and efficient. Our objective is to minimize the time and complexity of early-stage discovery, accelerate the development of innovative therapeutics, and expedite the delivery of new medications to patients.”
Industry Impact and Market Outlook
The global antibody discovery market is valued at USD 9.06 billion in 2025 and is expected to increase from USD 9.92 billion in 2026 to approximately USD 22.28 billion by 2035, expanding at a CAGR of 9.42% from 2026 to 2035. Growing investment in the pharmaceutical & biotechnology sector, rising prevalence of infectious diseases, and integration of AI in antibody discovery are boosting the market.
The recently launched automation center enables high-throughput experimental validation of AI-selected antibody candidates with minimal manual intervention, significantly accelerating the transition from molecular design to functional evaluation. The fully automated platform encompasses the entire protein production workflow, including bacterial inoculation, plasmid extraction, transfection, fed-batch cultivation, and purification.